Emerald Secures $2M Pre-Seed Funding to Revolutionize Healthcare with AI-Powered Blood Testing and Personalized Care
The healthcare industry is ripe for disruption, with a fragmented approach to health information management and a reactive model of care. Traditional general practice often waits for symptoms to appear before addressing health issues, leading to preventable complications. However, a new player, Emerald, is poised to change the game.
Emerald, a UK-based startup, has secured $2M in pre-seed funding to develop a comprehensive health management platform. By combining blood testing, AI technology, and personalized medical care, Emerald aims to provide a proactive approach to healthcare, catching potential issues before they become critical.
The company's innovative solution includes Baseline tests covering over 115 biomarkers, accessible at more than 50 UK locations. Users can track their health trends through a user-friendly dashboard and receive AI-powered alerts for potential health concerns. Additionally, an assigned GP provides diagnoses, prescriptions, and personalized action plans, ensuring a holistic approach to patient care.
The funding round was led by Boost Capital Partners, with participation from industry veteran Mark Fountain (former owner of HBS UK), Granatus Ventures, and several angel investors, including prominent Premier League players. Emerald's previous funding round, which raised £625K, was exclusively shared with TechFundingNews.com.
Emerald's market traction is impressive, with a user base that has more than tripled in the six months following its beta expansion. With over 25,000 tests processed and an impressive Net Promoter Score (NPS) of 80, the company has demonstrated a strong product-market fit.
Founded by CEO Alexander Badalyan in 2024, Emerald recognizes the potential of AI in healthcare while emphasizing the importance of medical nuance. CMO Dr. Daniel McNally, an active NHS clinician, ensures the platform maintains high clinical standards. The company's goal is to transform healthcare from reactive to proactive, providing real, trackable results.
Emerald's revenue model includes personal subscriptions and B2B partnerships with healthcare providers. By centralizing health data, adding AI insights, and incorporating GP oversight, Emerald offers a comprehensive solution. CEO Badalyan highlights the platform's unique ability to integrate with over 100 physical locations for bloodwork measurements and wearable data, providing a unified Health OS for preventative care.
Emerald stands out from competitors like Levels (metabolic health), Whoop and Oura (fitness tracking), and Torch Health (AI solution) by combining consumer-friendly design with clinically validated results. The company's diverse team, including first- and second-generation immigrants, brings a unique perspective to the high-growth healthtech startup environment.
Looking ahead, Emerald plans to expand in the UK, introduce new coaching programs in early 2026, and forge more partnerships with labs and imaging centers. Their scaling strategy involves collaborating with healthcare providers and employers, direct-to-consumer outreach, and targeted marketing to increase brand awareness.
